A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma. - Wikidata - wikimedia - TriplyDB

A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma.

A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma.

http://www.wikidata.org/entity/Q35245367

about

Advances in lung adenocarcinoma classification: a summary of the new international multidisciplinary classification system (IASLC/ATS/ERS)International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma Tracking genomic cancer evolution for precision medicine: the lung TRACERx study Tumour cell proliferation (Ki-67) in non-small cell lung cancer: a critical reappraisal of its prognostic role.Lepidic and micropapillary growth pattern and expression of Napsin A can stratify patients of stage I lung adenocarcinoma into different prognostic subgroup.Upregulation of KIN17 is associated with non-small cell lung cancer invasiveness Prognostic factors in resected lung carcinomas.Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease Implementing the new IASLC/ATS/ERS classification of lung adenocarcinomas: results from international and Chinese cohorts.The new IASLC-ATS-ERS lung adenocarcinoma classification: what the surgeon should know The cribriform pattern identifies a subset of acinar predominant tumors with poor prognosis in patients with stage I lung adenocarcinoma: a conceptual proposal to classify cribriform predominant tumors as a distinct histologic subtype.Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study.Solid Predominant Histologic Subtype in Resected Stage I Lung Adenocarcinoma Is an Independent Predictor of Early, Extrathoracic, Multisite Recurrence and of Poor Postrecurrence Survival The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers Tumor Spread through Air Spaces is an Important Pattern of Invasion and Impacts the Frequency and Location of Recurrences after Limited Resection for Small Stage I Lung Adenocarcinomas.Tumoral CD10 expression correlates with aggressive histology and prognosis in patients with malignant pleural mesothelioma.Tumoral CD10 expression correlates with high-grade histology and increases risk of recurrence in patients with stage I lung adenocarcinoma Using frozen section to identify histological patterns in stage I lung adenocarcinoma of ≤ 3 cm: accuracy and interobserver agreement.Tumor Budding Correlates With the Protumor Immune Microenvironment and Is an Independent Prognostic Factor for Recurrence of Stage I Lung Adenocarcinoma.Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation Inhibition of autophagy sensitizes malignant pleural mesothelioma cells to dual PI3K/mTOR inhibitors Nuclear estrogen receptor-α expression is an independent predictor of recurrence in male patients with pT1aN0 lung adenocarcinomas, and correlates with regulatory T-cell infiltration Comprehensive pathological analyses in lung squamous cell carcinoma: single cell invasion, nuclear diameter, and tumor budding are independent prognostic factors for worse outcomes.Thyroid transcription factor-1 expression is an independent predictor of recurrence and correlates with the IASLC/ATS/ERS histologic classification in patients with stage I lung adenocarcinoma Invasion Types Are Associated With Poor Prognosis in Lung Squamous Carcinoma Patients.Visceral pleural invasion does not affect recurrence or overall survival among patients with lung adenocarcinoma ≤ 2 cm: a proposal to reclassify T1 lung adenocarcinoma.Cell cycle progression score is a marker for five-year lung cancer-specific mortality risk in patients with resected stage I lung adenocarcinoma.Deciduoid mesothelioma: report of 21 cases with review of the literature.Unraveling tumor grading and genomic landscape in lung neuroendocrine tumors.Classification of different patterns of pulmonary adenocarcinomas.Histological features of malignancy correlate with growth patterns and patient outcome in lung adenocarcinoma.Histopathologic features predict survival in diffuse pleural malignant mesothelioma on pleural biopsies.KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules.Primary adenocarcinoma of the lung--histological subtypes and outcome after surgery, using the IASLC/ATS/ERS classification of lung adenocarcinoma.Cytomorphological features of ALK-positive lung adenocarcinomas: psammoma bodies and signet ring cells.Tumor cell proliferation, proliferative index and mitotic count in lung cancer.What is better/reliable, mitosis counting or Ki67/MIB1 staining?Does immunohistochemistry affect response to therapy and survival of inoperable non-small cell lung carcinoma patients? A survey of 145 stage III-IV consecutive cases.Association of Omics Features with Histopathology Patterns in Lung Adenocarcinoma.

P2860

Q27009370-70123722-B3B4-4097-9556-C97F508ED9D9 Q28303718-4E154184-ABCC-4522-B660-3D28F4022913 Q28655985-E10A4175-0384-476E-AC6A-EE6926260F9D Q30652903-729BE096-217C-48A9-98E8-B3EFAF31816E Q33582932-A2F685F5-A2EA-4B7E-9C88-13648B4C8064 Q33597902-0DFAF4E5-3FD4-450A-9C90-958B28E0DF2C Q33697964-69D6E13F-84AF-4781-AD89-3974AA4E95B4 Q34181641-7545EED4-B673-43FD-9137-14E27E86F4FB Q34404229-BF1E4E3B-8D8A-4D3A-93EB-8EE16C8ACF94 Q34748124-EAF4BE2C-2B10-4334-9005-42B3BF7B9342 Q35219157-2430AC81-7D3E-43EC-B42E-BD52B75AA1D1 Q35678741-AFAD3B48-7AB6-403F-8637-07936FC25F8B Q35742165-44093213-8051-43C8-86EB-829A9D82C4CD Q35799028-18A4D95E-C107-4445-983C-A950987A0CE8 Q35845212-ADCB66E0-8AE6-4D7A-AFC4-1BB1032615A7 Q35880415-D405F262-55FC-4A42-AEF2-4B8914C3F336 Q35940727-7AB8C570-B523-4F13-A015-EDC1B2F0DD77 Q35954585-4B8386D1-5AFB-42AE-AFEA-7CB40081E699 Q36015463-471BC20C-9DFE-4313-9734-77A61E074D65 Q36337437-D5A31425-51A4-4FB8-BB75-636FE2EA69DD Q36346942-88EB1788-1FBA-4FDF-BFB4-30EFFF7B4BF0 Q36413817-592568BD-593D-4552-80AB-41C041D7A2DE Q36726239-E9E74845-A48F-41DD-A581-ECABA594E005 Q36952749-18C03F6E-3FC4-4373-8D73-F22DE38C4D7D Q37176131-3B7C3E9D-32F3-4A11-88DB-436CBC985F3E Q37280912-0C7D7CAB-A576-4526-9A44-6AE49753AE76 Q37376521-9B728282-F6F8-4341-9C2F-E3A1BB7FDC8B Q38017572-27DDF97E-AC6A-40C8-86B2-379D661E9814 Q38207553-B49EE3DE-107C-4E0B-B741-E85DC7427591 Q38574971-288867C6-2F28-4E80-B070-A761AB932DAF Q38841094-94733F13-38A4-4888-944D-4295AA1DB133 Q40270889-F4B5F3AC-2940-497B-9C9F-B8D944B3E240 Q40542208-52E8408C-7BFD-409D-B8F2-472C5CDE9C73 Q40812047-2BA3850A-F8AB-45FF-8852-91467880F9FF Q40864750-A350B79B-89B9-492E-8835-265787FE1EEB Q41627914-D76108E7-2B0F-430E-BC31-AE0CB3B535FE Q42372532-4AEA1B7B-14E6-4C10-9DF2-D558C239BFD8 Q42372536-DF4D317D-35C0-4D29-9E56-63082F345FBD Q45276482-34E6861A-1C2B-4494-A61A-45B75425C8BE Q45943784-956B8A0E-931C-4D49-A609-94CD01AB8137

P2860

A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma.

http://www.wikidata.org/entity/Q35245367

description

2012 nî lūn-bûn

@nan

2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

A grading system combining arc ...... n stage I lung adenocarcinoma.

@ast

A grading system combining arc ...... n stage I lung adenocarcinoma.

@en

type

label

A grading system combining arc ...... n stage I lung adenocarcinoma.

@ast

A grading system combining arc ...... n stage I lung adenocarcinoma.

@en

prefLabel

A grading system combining arc ...... n stage I lung adenocarcinoma.

@ast

A grading system combining arc ...... n stage I lung adenocarcinoma.

@en

P1433

Q35245367-6985B26A-06B1-4158-949F-FDEDAFC42A37

P1476

Q35245367-4713CA15-5C73-4EA3-A498-AE68D83B184E

P2093

Q35245367-1BBEFF0C-BEF5-4AA4-A7DB-56F4EA3779D7

Q35245367-3E73DF75-BDAB-4D4F-BF39-5EEC9E110514

Q35245367-4A5E3C1F-72EF-46A5-843D-07B12A625119

Q35245367-4ACDACCF-E9C1-452F-AA09-99B577563A02

Q35245367-5628446E-BA9C-4FE8-96D6-4BFD7F096AA5

Q35245367-56F2A7F0-46A2-4B34-B8B8-FDA0328BEE50

Q35245367-6D8CBE1C-880C-4784-A76F-84568E7B54EB

Q35245367-9F50EB4E-19C7-44A8-8D2C-13146626AF21

Q35245367-AAD838B3-FB66-42DD-B640-91062E65D62F

Q35245367-DA37D20B-FD17-4585-A332-49662FFF65D8

P2860

Q35245367-003E2AEE-504D-442D-BFA2-FFE7BBC59120

Q35245367-015E155C-4B6F-4AFC-AD41-EF67782DB081

Q35245367-09721FCB-E255-4932-9769-5B0A3C9376B5

Q35245367-18AC81C8-73CD-4719-ABEF-824A0D289AC2

Q35245367-244A54C8-9424-4880-B28E-6A9E62D3E128

Q35245367-289AFD8D-1DAF-4859-B65C-46DC08001125

Q35245367-2D86310F-55F9-4C39-B15B-60B26230B10B

Q35245367-42117001-16B2-4BDB-900B-DE00B4EAF551

Q35245367-46DA99BD-2B6B-49E4-97CE-4D8FAD375451

Q35245367-66346D01-CB80-404C-B614-DB1DAC18F3D8

P2888

Q35245367-188D90AF-0EB2-4340-BB01-78E481521536

P304

Q35245367-C8197A1F-CEA9-4FF1-901A-016C729DC806

P31

Q35245367-5F6B04FA-BF9A-41A1-89ED-AD9BD7768487

P356

Q35245367-21D9F53D-0007-4615-AE63-62064453263D

P433

Q35245367-096EAF73-CC86-46D5-88B3-16DEB8AF26FC

P478

Q35245367-6FD071EE-2E5C-4260-8FC7-81ACD73C0C6E

P577

Q35245367-ECEC1CF7-CDC9-4909-A6CD-3F37DABF076D

P5875

Q35245367-815390B9-3D9A-417D-8927-3455A49706D8

P6179

Q35245367-2DC4F42D-EF77-4C7A-B50B-75BBC558377E

P698

Q35245367-F8D2B519-FF44-4E73-B6A5-96ECC32D9365

P921

Q35245367-144BD239-75C9-400B-A278-714C5555F55F

P932

Q35245367-7EE17D67-A0AD-4474-A364-B3FDF4B42C7B

P356

MODPATHOL.2012.58

P1433

Modern Pathology

P1476

A grading system combining arc ...... n stage I lung adenocarcinoma.

@en

P2093

Akihiko Yoshizawa

http://www.w3.org/2001/XMLSchema#string

Andre L Moreira

http://www.w3.org/2001/XMLSchema#string

Camelia S Sima

http://www.w3.org/2001/XMLSchema#string

Emily C Zabor

http://www.w3.org/2001/XMLSchema#string

Gregory J Riely

http://www.w3.org/2001/XMLSchema#string

Kei Suzuki

http://www.w3.org/2001/XMLSchema#string

Kyuichi Kadota

http://www.w3.org/2001/XMLSchema#string

Prasad S Adusumilli

http://www.w3.org/2001/XMLSchema#string

Stefan S Kachala

http://www.w3.org/2001/XMLSchema#string

Valerie W Rusch

http://www.w3.org/2001/XMLSchema#string

P2860

Prognostic value of proliferation in invasive breast cancer: a review

International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma

Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.

Clinically relevant characterization of lung adenocarcinoma subtypes based on cellular pathways: an international validation study.

Prognostic significance of grading in lung adenocarcinoma.

Gene expression-based prognostic signatures in lung cancer: ready for clinical use?

Lung adenocarcinoma with mixed bronchioloalveolar and invasive components: clinicopathological features, subclassification by extent of invasive foci, and immunohistochemical characterization.

Prognostic ability of simplified nuclear grading of renal cell carcinoma.

Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis.

The new World Health Organization/International Society of Urological Pathology (WHO/ISUP) classification for TA, T1 bladder tumors: is it an improvement?

P2888

modpathol.2012.58

P304

1117-1127

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MODPATHOL.2012.58

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2012-04-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224005726

http://www.w3.org/2001/XMLSchema#string

P6179

1051896844

http://www.w3.org/2001/XMLSchema#string

P698

22499226

http://www.w3.org/2001/XMLSchema#string

P921

P932

4382749

http://www.w3.org/2001/XMLSchema#string